182 related articles for article (PubMed ID: 26842345)
1. Giant Cell Tumor of Bone With Pseudosarcomatous Changes Leading to Premature Denosumab Therapy Interruption: A Case Report With Review of the Literature.
Sanchez-Pareja A; Larousserie F; Boudabbous S; Beaulieu JY; Mach N; Saiji E; Rougemont AL
Int J Surg Pathol; 2016 Jun; 24(4):366-72. PubMed ID: 26842345
[TBL] [Abstract][Full Text] [Related]
2. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
3. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
4. Pseudosarcomatous Spindle Cell Proliferation With Osteoid Matrix Mimicking Osteosarcoma: A Distinct Histologic Phenotype in Giant Cell Tumor of Bone Following Denosumab Therapy.
Santosh N; Mayerson JL; Iwenofu OH
Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):e18-9. PubMed ID: 25789537
[No Abstract] [Full Text] [Related]
5. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
6. Histopathological response to denosumab in giant cell tumours of bone - A review of 11 cases.
Kumar R; Mallya V; Mandal S; Tomar R; Khurana N; Maini L
J Cancer Res Ther; 2023; 19(3):768-772. PubMed ID: 37470608
[TBL] [Abstract][Full Text] [Related]
7. A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab.
Aponte-Tinao LA; Piuzzi NS; Roitman P; Farfalli GL
Clin Orthop Relat Res; 2015 Sep; 473(9):3050-5. PubMed ID: 25758379
[TBL] [Abstract][Full Text] [Related]
8. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
9. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
10. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
Lipplaa A; Dijkstra S; Gelderblom H
Curr Opin Oncol; 2019 Jul; 31(4):329-335. PubMed ID: 30844887
[TBL] [Abstract][Full Text] [Related]
11. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
12. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery.
von Borstel D; A Taguibao R; A Strle N; E Burns J
Skeletal Radiol; 2017 Apr; 46(4):571-578. PubMed ID: 28188337
[TBL] [Abstract][Full Text] [Related]
13. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
14. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab].
Gong LH; Liu WF; Ding Y; Zhang W; Yang YK; Yu F; Wong GQ; Huang XY; Niu XH
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):449-454. PubMed ID: 29886590
[No Abstract] [Full Text] [Related]
15. Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.
Park A; Cipriano CA; Hill K; Kyriakos M; McDonald DJ
JBJS Case Connect; 2016; 6(3):e78. PubMed ID: 29252655
[TBL] [Abstract][Full Text] [Related]
16. Denosumab: Current Use in the Treatment of Primary Bone Tumors.
Savvidou OD; Bolia IK; Chloros GD; Papanastasiou J; Koutsouradis P; Papagelopoulos PJ
Orthopedics; 2017 Jul; 40(4):204-210. PubMed ID: 28732103
[TBL] [Abstract][Full Text] [Related]
17. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of RANKL Expression in Osteocyte-like Differentiated Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment.
Noguchi T; Sakamoto A; Murotani Y; Murata K; Hirata M; Yamada Y; Toguchida J; Matsuda S
J Histochem Cytochem; 2023 Mar; 71(3):131-138. PubMed ID: 36971322
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]